

# NHL: Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Pathways

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_ Treatment Start Date: \_\_\_\_\_

ICD-10 Code: \_\_\_\_\_ Pathology: \_\_\_\_\_

**Lymphoma Stage:** \_\_0 \_\_0-E \_\_0-X \_\_0-XE \_\_IA \_\_IA-E \_\_IA-X \_\_IA-XE \_\_IB \_\_IB-E \_\_IB-X \_\_IB-XE \_\_IIA \_\_IIA-E \_\_IIA-X \_\_IIA-XE \_\_IIB \_\_IIB-E \_\_IIB-X \_\_IIB-XE \_\_IIIA \_\_IIIA-E \_\_IIIA-X \_\_IIIA-XE \_\_IIIB \_\_IIIB-E \_\_IIIB-X \_\_IIIB-XE \_\_IVA \_\_IVA-E \_\_IVA-X \_\_IVA-XE \_\_IVB \_\_IVB-E \_\_IVB-X \_\_IVB-XE \_\_NS \_\_Recurrent

**Leukemia Stage:** \_\_NS (No stage) \_\_Recurrent

**Line of Treatment:** \_\_First Line \_\_Second Line \_\_Third Line \_\_Third Line+ \_\_Maintenance

**ECOG Performance Status:** \_\_0 \_\_1 \_\_2 \_\_3 \_\_4

## Biomarkers:

11q deletion: \_\_Absent \_\_Present

17p deletion: \_\_Absent \_\_Present

CD20 Status: \_\_Negative \_\_Positive

TP53 status: \_\_Mutation Absent \_\_Mutation Present

## First line of therapy (1<sup>st</sup> line) | With 17p Deletion

\_\_Ibrutinib (Imbruvica)

## First line of therapy (1<sup>st</sup> line) | Without 17p Deletion

\_\_BR: bendamustine (Bendeka, Treanda) and rituximab (Rituxan)

\_\_FCR: fludarabine (Fludara), cyclophosphamide, and rituximab (Rituxan)

\_\_Ibrutinib (Imbruvica)

\_\_Obinutuzumab (Gazyva) and chlorambucil (Leukeran)

Indications to initiate treatment may include (not limited to):

- 1 WBC elevation above  $200-300 \times 10^9$
- 2 Signs of leukostasis
- 3 Lymphocyte doubling time of less than 6 months
- 4 In low or intermediate risk disease:
  - a. Significant disease-related symptoms such as severe fatigue, weight loss, night sweats, otherwise unexplained fever
  - b. Signs of end-organ damage
  - c. Significant or progressive bulky disease, such as massive splenomegaly ( $\geq 6$  cm below the costal margin) or massive lymphadenopathy ( $> 10$  cm in longest diameter)
  - d. Clinically significant progressive or symptomatic anemia or thrombocytopenia
    - i. Not caused by autoimmune etiology, unless poor response to conventional immunosuppressive therapy

High risk disease, particularly with progressive cytopenias

**Note:** Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.



8600 West Bryn Mawr Avenue  
South Tower - Suite 800 Chicago, IL 60631  
[www.aimspecialtyhealth.com](http://www.aimspecialtyhealth.com)

Last review: 8/29/2017 | Effective date: 11/1/2017

Appropriate.Safe.Affordable  
© 2017 AIM Specialty Health  
9005-1117b

# NHL: Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Pathways (continued)

## Second and subsequent lines of therapy (2<sup>nd</sup> line +) | With 17p Deletion

- \_\_\_ Ibrutinib (Imbruvica)
- \_\_\_ Idelalisib (Zydelig)
- \_\_\_ Idelalisib (Zydelig) and rituximab (Rituxan)

## Second and subsequent lines of therapy (2<sup>nd</sup> line +) | Without 17p Deletion

- \_\_\_ **BR**: bendamustine (Bendeka, Treanda) and rituximab (Rituxan)
- \_\_\_ Ibrutinib (Imbruvica)
- \_\_\_ Idelalisib (Zydelig)
- \_\_\_ Idelalisib (Zydelig) and rituximab (Rituxan)

Indications to initiate treatment may include (not limited to):

- 1 WBC elevation above  $200-300 \times 10^9$
- 2 Signs of leukostasis
- 3 Lymphocyte doubling time of less than 6 months
- 4 In low or intermediate risk disease:
  - a. Significant disease-related symptoms such as severe fatigue, weight loss, night sweats, otherwise unexplained fever
  - b. Signs of end-organ damage
  - c. Significant or progressive bulky disease, such as massive splenomegaly ( $\geq 6$  cm below the costal margin) or massive lymphadenopathy ( $> 10$  cm in longest diameter)
  - d. Clinically significant progressive or symptomatic anemia or thrombocytopenia
    - i. Not caused by autoimmune etiology, unless poor response to conventional immunosuppressive therapy

High risk disease, particularly with progressive cytopenias

**Note:** Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

